Humedix and G2GBIO to work together on long-acting drugs

Home > Business > Industry

print dictionary print

Humedix and G2GBIO to work together on long-acting drugs

Humedix CEO Kim Jin-hwan, left, and G2GBIO CEO Lee Hee-yong, pose for a photo after signing an agreement to cooperate in developing long-acting injectable drugs. [HUMEDIX]

Humedix CEO Kim Jin-hwan, left, and G2GBIO CEO Lee Hee-yong, pose for a photo after signing an agreement to cooperate in developing long-acting injectable drugs. [HUMEDIX]

 
Humedix signed an agreement with Daejeon’s G2GBIO to cooperate on the development of long-acting injectable drugs, the Kosdaq-listed biopharmaceutical company said Tuesday.
 
Long-acting injectable drugs refer to those that persist in the body for an extended period of time. The intervals between injections can be between about one month and three months, unlike to conventional drugs that must be injected or consumed every day.
 
Under the agreement, Humedix, 40.64 percent owned by Huons Global, will help with the development and marketing of GB5001, a G2GBIO treatment candidate for Alzheimer’s disease. G2GBIO has been developing an Alzheimer’s disease treatment that is effective in the body for about one month per injection.
 
The two companies will also join forces to develop treatments for various rare intractable diseases.
 
“By sharing our strengths, Humedix and G2GBIO will develop long-acting injectable drugs that can have competitiveness in the global market.” Humedix CEO Kim Jin-hwan said in a statement.  
 
About 76 million people will be suffering from Alzheimer’s disease in 2030, and 135 million by 2050, according to data from the Alzheimer’s Association. The size of global Alzheimer’s disease treatment market will likely grow to $12.6 billion in 2024 from $2.9 billion last year.
 

BY SARAH CHEA [chea.sarah@joongang.co.kr]
Log in to Twitter or Facebook account to connect
with the Korea JoongAng Daily
help-image Social comment?
s
lock icon

To write comments, please log in to one of the accounts.

Standards Board Policy (0/250자)

What’s Popular Now